{"id":"W2977799542","doi":"10.1093/annonc/mdz250.036","title":"Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Bevacizumab; Carboplatin; Ovarian cancer; Folate receptor; Antibody-drug conjugate; Conjugate; Oncology; Internal medicine; Phases of clinical research; Antibody; Cancer research; Cancer; Chemotherapy; Monoclonal antibody; Immunology; Cisplatin; Cancer cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007378893,0.0005744962,0.001446199,0.0003379989,0.0002429279,0.0006645097,0.0004334042,0.0005657751,0.001637243],"category_scores_gemma":[0.0008261742,0.0003817394,0.0006657724,0.0004107873,0.0004118874,0.0005814618,0.0002454841,0.001822112,0.0003902933],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006500281,"about_ca_system_score_gemma":0.0007470919,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00145766,"about_ca_topic_score_gemma":0.004574943,"domain_scores_codex":[0.9997576,0.000106146,0.00001417092,0.00004118167,0.00003275577,0.00004813899],"domain_scores_gemma":[0.9996848,0.00007622408,0.00005304442,0.00001807593,0.00002101482,0.0001468606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5053353,0.03271103,0.01562537,0.00137668,0.002296605,0.0004939105,0.0005072347,0.004405482,0.1085211,0.0003396291,0.00364744,0.3247401],"study_design_scores_gemma":[0.3172193,0.5878595,0.05652187,0.0000959574,0.001601013,0.00131213,0.000220722,0.004658578,0.02082487,0.0002166012,0.009410559,0.00005884455],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945329,0.002981397,0.0002822596,0.0002342218,0.00006322449,0.0002771257,0.0002008117,0.00006631875,0.001361608],"genre_scores_gemma":[0.9942839,0.002439075,0.0008081102,0.0002283238,0.00006357992,0.0001441838,0.0006529717,0.00002076586,0.001359203],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001637243,"threshold_uncertainty_score":0.00547713,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03156606835158248,"score_gpt":0.370214216494396,"score_spread":0.3386481481428135,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}